Approved for marketing Expanded access trials in the Netherlands

Showing 1 to 7 of 7. Each trial links to its page on Pharma Observatory.

• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer NCT00338247·Expanded access·Approved for marketing·Novartis·Started 2006
• Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897·Expanded access·Approved for marketing·Pfizer·Started 2005
• A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 NCT00094029·Expanded access·Approved for marketing·Pfizer·Started 2004
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs NCT00354627·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer NCT02065765·Expanded access·Approved for marketing·Eli Lilly and Company
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) NCT04323761·Expanded access·Approved for marketing·Gilead Sciences